Ovid Therapeutics Inc. (OVID) Return on equity 2020–2025
Ovid Therapeutics Inc. (OVID) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-13.3%FY2025 · since FY2020: -185.7% → -13.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -13.3% | +25.4 pp |
| FY2024 | -38.7% | +20.9 pp |
| FY2023 | -59.6% | -18.7 pp |
| FY2022 | -41.0% | -109.3 pp |
| FY2021 | 68.3% | +254.1 pp |
| FY2020 | -185.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More OVID financial trends
OVID RevenueOVID Net incomeOVID Net marginOVID Gross profitOVID Gross marginOVID Operating incomeOVID Operating marginOVID Operating cash flowOVID Free cash flowOVID Capital expendituresOVID Stock buybacksOVID Dividends paidOVID Total assetsOVID Total liabilitiesOVID Shareholders’ equityOVID overview →